Testing a new combination treatment for breast cancer that has spread to the brain

Plain-English translation of NCT06793332 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether combining two newer medications—ivonescimab and a TROP2 antibody-drug conjugate—can help treat triple-negative breast cancer that has spread to the brain. These medications work differently than traditional chemotherapy: one boosts your immune system and blocks blood vessel growth to starve tumors, while the other directly targets and kills cancer cells. The trial aims to see if this combination can help patients live longer and feel better.

Triple-negative breast cancer that spreads to the brain is very serious, with patients often surviving less than 6 months without effective treatment. Recent research has shown that combinations of newer, targeted drugs work better than older treatments, but they haven't been specifically tested in patients with brain metastases yet. This trial exists to find out whether this medication combination can improve survival for this group of patients.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have triple-negative breast cancer that has spread to the brain and has not responded to or returned after taxane chemotherapy
you have at least one brain tumor that is at least 1 centimeter across and has not been treated with radiation
you have adequate heart, liver, and kidney function and are in reasonably good health overall
you can provide tissue samples from your cancer for research purposes
you understand the study and are willing to sign a consent form

You likely don't qualify if…

you have cancer that has spread to the membrane surrounding your brain and spinal cord
you have large amounts of fluid buildup in your chest or abdomen that cannot be drained
you have recently received radiation, chemotherapy, surgery, or other cancer treatments (within 1–2 weeks)
you have previously taken medications that block both PD-1/PD-L1 and VEGF, or have used this type of antibody-drug conjugate before
you have severe heart disease, including heart failure, recent heart attack, or unstable chest pain

What participation looks like

You would receive the two-drug combination treatment, likely as infusions at a medical center. The trial is enrolling 39 patients total and will track how well the treatment works and how you tolerate it over time. You'll have regular visits for blood work, imaging scans of your brain, and check-ins with your medical team to monitor your response and any side effects. The exact schedule of visits and treatment duration would be explained in detail by the research team before you enroll.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Fudan University Shanghai Cancer center, Shanghai, Shanghai Municipality